Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tardive dyskinesia
Marketing
Neurocrine data make case for timely movement disorder diagnosis
Neurocrine shared survey data showing how tardive dyskinesia affects patients' and caregivers' work, supporting its case for timely treatment.
Nick Paul Taylor
May 5, 2026 6:03am
Teva's innovative drugs helped carry strong Q1
Apr 29, 2026 2:27pm
Teva drafts Terrell Davis for tardive dyskinesia awareness drive
Nov 5, 2025 12:49pm
Teva forecasts $5B-plus in innovative drug sales by 2030
May 30, 2025 7:20am
Neurocrine taps Wilson Phillips star for tardive dyskinesia push
May 6, 2025 11:16am
Neurocrine's Ingrezza guidance spooks investors
Feb 10, 2025 9:13am
